Following U.S. Stocks were among the “Top Losers” during Friday’s trade: DCT Industrial Trust Inc (NYSE:DCT), EXCO Resources Inc (NYSE:XCO), Parkway Properties Inc (NYSE:PKY), Hemispherx BioPharma, Inc (NYSEMKT:HEB)
Their insights are depicted underneath:
DCT Industrial Trust Inc (NYSE:DCT)’s shares dwindled -4.58%, and closed at $33.54.
DCT Industrial Trust Inc. (DCT), a leading industrial real estate corporation, declared that Philip Hawkins, Chief Executive Officer, presented at the Citi 2015 Global Property CEO Conference. The presentation was on Tuesday, March 3, 2015.
DCT Industrial is a leading industrial real estate corporation specializing in the attainment, development, leasing and administration of bulk distribution and light industrial properties in high-volume distribution markets in the U.S.
EXCO Resources Inc (NYSE:XCO) declined -4.55%, and closed at $1.89.
According to BUSINESS WIRE, on February 25, EXCO Resources Inc. (XCO), declared that it has filed a post-effective amendment to its existing automatic shelf registration statement, filed with the Securities and Exchange Commission on January 30, 2014, related to the resale of shares of EXCO’s ordinary stock held by certain selling shareholders. EXCO filed the Original Registration Statement for the resale of shares held by the Selling Shareholders who either attained their shares in a private transaction and/or are considered associates of EXCO.
The Original Registration Statement was filed as an automatic shelf registration statement. Due to the recent decline in the trading price of EXCO’s ordinary stock, EXCO did not meet the requirements to maintain an automatic shelf registration statement at the time EXCO filed its Annual Report on Form 10-K for the year ended December 31, 2014. Accordingly, EXCO filed a post-effective amendment to the Original Registration Statement to convert the Original Registration Statement to a non-automatic shelf registration statement which, when declared effective by the SEC, will permit the Selling Shareholders to resell shares following the Amended Registration Statement. EXCO filed the Amended Registration Statement to comply with the terms of a registration rights contract between EXCO and the Selling Shareholders. The SEC has not yet declared the Amended Registration Statement effective.
EXCO Resources, Inc. is an oil and natural gas exploration, exploitation, development and production corporation headquartered in Dallas, Texas with principal operations in Texas, North Louisiana and Appalachia.
Parkway Properties Inc (NYSE:PKY) dipped -4.54%, and closed at $16.82, hitting new 52-week low of $16.60.
Parkway Properties Inc. (PKY), declared that it presented at the Citi 2015 Global Property CEO Conference on Wednesday, March 4, 2015 at The Diplomat Resort & Spa in Hollywood, Florida.
Parkway Properties, Inc. is a fully integrated, self-administered and self-managed real estate investment trust specializing in the attainment, ownership, development and administration of quality office properties in higher growth submarkets in the Sunbelt region of the United States.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) dropped -4.43%, and closed at $0.248.
According to GLOBE NEWSWIRE, Hemispherx Biopharma, Inc. (HEB), declared that its manufacturing site located in New Brunswick, New Jersey, presently configured at over 43,000 square feet, has accomplished its $8 million of upgrades. These upgrades will provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection(R), the only FDA-approved natural alpha interferon. The added efficiency of the process has been accomplished by integrating continuous flow manufacturing technology throughout the process. This has led to improved cost efficiency, improved yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety as seen in other cutting edge pharmaceutical companies.
The upgraded facility is installed with a 600-liter bioreactor instead of a labor-intensive method using 100 x 6 liter flasks for the same size batch. Scaling up to the automated 600-liter bioreactor has eliminated ~ 80% of the manpower formerly needed for this part of the process.
In March 2008, the corporation halted the manufacturing and marketing of Alferon N Injection(R) due to the high labor cost for manufacturing Alferon(R) and the low capacity significantly limiting the commercialization potential of Alferon N Injection(R). The original process, producing the Alferon(R) in hundreds of small flasks, was extremely labor intensive. The upgraded manufacturing facility which uses a 600-liter bioreactor will provide a cost effective process and provide the capacity to supply both the US and South American market. The FDA will need to re-affirm the amended Biological License Application (BLA) for the facility before the commercial sales of Alferon N Injection(R) are recommenced. The corporation is anticipating having commercial product accessible for distribution by Armada Healthcare by late 2015.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical corporation engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders especially life-threatening viruses. Hemispherx’s flagship products comprise Alferon(R) N Injection(R) and the experimental therapeutics Ampligen(R) and Alferon(R) LDO. Ampligen(R) is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, counting Chronic Fatigue Syndrome.
